Investors

Download Investor Presentation

Company Overview

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix™ is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.

Most Recent Shareholder Letter

Email Alerts

Stay informed and receive company updates straight to your inbox

Recent News

AXIM Biotechnologies CEO Issues Letter to Shareholders

  Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2020

Investor Contact Information

Company

AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E., Suite 114,    San Diego, CA 92121
T: +1 858 923-4422

Investor Relations

Transfer Agent

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com